| GX15-070 MDS / AML (single agent) |
Protocol ID GX006 |
A Multi-Center, Open-Label, Phase I Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks or Weekly, or as a Prolonged Intravenous Infusion Every 2 to 3 Weeks to Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase, Myelofibrosis, Previously-Treated Chronic Lymphocytic Leukemia (CLL), or aplastic anemia. |
| Click here for trial details and contact information |
|
| Associated Links |
|
| Small Molecule Pan-Bcl2 Family Inhibitor Obatoclax (GX15-070): Overview of Clinical Phase I Study Results. Chemotherapy Foundation Symposium 2006 |
|
|
|
|
| GX15-070 MCL (Bortezomib) |
Protocol ID GEM012 |
A Phase I Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination with Bortezomib to Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
| Click here for trial details and contact information |
|
|
|
| GX15-070 NSCLC (+ Docetaxel) |
Protocol ID GEM010 |
A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered Every 3 Weeks in Combination with Docetaxel to Patients with Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) |
| Click here for trial details and contact information |
|
|
|
| GX15-070 Hodgkin’s Lymphoma (single agent) |
Protocol ID GEM011 |
A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients with Relapsed or Refractory Hodgkin’s Lymphoma (HL) |
| Click here for trial details and contact information |
|
|
|
| GX15-070 Myelofibrosis (single agent) |
Protocol ID GEM007 |
A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients with Myelofibrosis with Myeloid Metaplasia (MF) |
| Click here for trial details and contact information |
|
|
|
| GX15-070 MDS (with Anemia and/or Thrombocytopenia) |
Protocol ID GEM013 |
A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS in Patients with Previously Untreated Myelodysplastic Syndromes (MDS) with Anemia and/or Thrombocytopenia |
| Click here for trial details and contact information |
|
|
|
| GX15-070 Follicular Lymphoma (+ Rituxan) |
Protocol ID GEM014 |
A Multi-Center, Open-Label, Phase II Study of Sequential, Single-Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination with Rituximab to Patients with Previously-Untreated Follicular Lymphoma (FL) |
| Click here for trial details and contact information |
|
|
|
| GMX1777 |
Protocol ID GEM301 |
A Single-Center, Open-Label, Phase 1 Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients with Refractory Solid Tumors or Lymphomas. |
| Click here for trial details and contact information |
|
